Developing a highly robust, efficient, and cost-effective monoclonal antibody workflow

Since the COVID-19 pandemic, pressure has increased to develop more products for treating unexpected viral diseases at reduced costs, under safe conditions and in a timely manner. Monoclonal antibodies (mAbs) may hold great promise to fill this gap as an addition to vaccines and anti-viral drugs. Eppendorf has curated a mAb workflow to increase reproducibility and productivity of mAb research and development process. Explore how you can optimize process development, scale up, and device management to maximize yields and prevent instrument downtime.